CCRL2 Programme

One of the GPCRs identified by Oxagen as genetically associated with a range of inflammatory diseases is the orphan C-C-chemokine receptor CCRL2. This receptor, also known as HCR, CRAM-A, CRAM-B, CKRX and Eo1 is found strongly expressed on macrophages and has an alternative spliced variant produced on activated macrophages. We have de-orphanised this receptor and shown that the major ligand for this receptor is the orphan chemokine MIP-4, also known as CCL-18, PARC, DC-CK-1 and AMAC-1. Many reports detail the putative roles of one or both of these biological molecules in the pathogenesis of rheumatoid arthritis, atherosclerosis, respiratory diseases, inflammatory bowel disease and allergic dermatitis.
We are seeking partners to help us develop biologics and small molecule agents which interfere with this receptor / ligand interaction with a view to developing therapeutics to treat a broad range of immune and inflammatory disorders.

Click here for further information on Oxagen's CCRL2 programme